Alex Fotopoulos
Chief Tech/Sci/R&D Officer chez PASSAGE BIO, INC.
Fortune : 38 736 $ au 31/03/2024
Profil
Alex Fotopoulos is currently the Chief Technical Officer at Passage Bio, Inc. He previously worked as the Senior Director-Global Manufacturing Engineering at Biogen, Inc. from 1994 to 2011, Vice President-Technical Operations at Momenta Pharmaceuticals, Inc. from 2011 to 2016, Senior Vice President & Head-Technical Operations at Dimension Therapeutics, Inc. in 2016-2017, and Senior Vice President-Technical Operations at Ultragenyx Pharmaceutical, Inc. from 2017 to 2019.
Fotopoulos received a graduate degree from Tufts University in 1997 and an MBA from F.W.
Olin Graduate School of Business in 1998.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PASSAGE BIO, INC.
0,05% | 16/06/2023 | 28 693 ( 0,05% ) | 38 736 $ | 31/03/2024 |
Postes actifs de Alex Fotopoulos
| Sociétés | Poste | Début |
|---|---|---|
| PASSAGE BIO, INC. | Chief Tech/Sci/R&D Officer | 01/07/2019 |
Anciens postes connus de Alex Fotopoulos
| Sociétés | Poste | Fin |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 01/07/2019 |
| DIMENSION THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 01/11/2017 |
| MOMENTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2016 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2011 |
Formation de Alex Fotopoulos
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| PASSAGE BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
